Survodutide

InvestigationalMetabolic ResearchWeight & metabolic
5.1

Neutral, BioHarmony verdict

BioHarmony score 5.1 out of 10

Survodutide (BI 456906) is an investigational once-weekly GLP-1 and glucagon dual agonist that drove up to 16.6% weight loss in Phase 3, per the Boehringer Ingelheim SYNCHRONIZE-1 topline, and 62% liver-disease improvement on its best Phase 2 dose, per Sanyal 2024.

Read full report

What is Survodutide?

Survodutide, also called BI 456906, is an investigational injectable peptide that hits two receptors at once: GLP-1 and glucagon. The GLP-1 arm is the familiar one. It blunts appetite and slows the stomach, the same way semaglutide does. The glucagon arm is the twist. It tells the liver to burn its own fat and adds a little extra heat production on top.

From the BioHarmony report, reviewed Sep 8, 2026.

Saved on this device only.

How it is thought to work

GLP-1 arm cuts appetite and slows the gut; glucagon arm burns liver fat and adds thermogenesis

Safety watch-outs

  • Severe, persistent stomach pain that may travel to the back (possible pancreatitis): stop and seek care.
  • Relentless vomiting with signs of dehydration: stop and consult a clinician.
  • New or worsening fast or irregular heartbeat: reduce dose or stop and get evaluated.
  • Any personal or family history of medullary thyroid cancer or MEN 2: do not use, consistent with the GLP-1 class warning.

Full risk profile in the BioHarmony report.

Dosing as published

Source-reported figures only. This page does not calculate a personal dose.

No approved-label or study protocol is recorded for Survodutide yet.

More reported protocols

Members

Members can compare additional reported doses, schedules, and preparation notes.

Trust & sourcing

  1. Last revieweddone
  2. Next reviewupcoming
US approvalInvestigational
CompoundingNo FDA-approved product; compounding eligibility is not established

Survodutide is an investigational glucagon and GLP-1 dual receptor agonist developed by Boehringer Ingelheim under a partnership with Zealand Pharma. Registered phase 3 studies cover obesity and metabolic dysfunction-associated steatohepatitis, and there is no FDA-approved survodutide product.

Primary sources

The Ultimate Peptides Guide

Spot stronger candidates, weak evidence, and seller red flags before you buy.

Free. Includes evidence and regulatory updates. Unsubscribe anytime.